ORGO’s main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. Click here to find out why ORGO is a Buy.

Home News Business Earnings Jaysynth Orgo Standalone March 2025 Net Sales at Rs 59.21 crore, up 12.11% Y-o-Y Trending Topics Q4 Results 2025 LiveNykaa Q4 resultsOla Electric Q4 ResultsBajaj Auto ...

Organogenesis Holdings Inc (NASDAQ:ORGO) is set to release its Q1 2025 earnings on May 8, 2025. The consensus estimate for Q1 2025 revenue is $90.77 million, and the earnings are expected to come ...

Michael Joseph Driscoll, a director at $ORGO, sold 25,000 shares of the company on 03-04-2025 for an estimated $127,535. We received data on the trade from a recent SEC filing.

Ethers — such as the widely used tetrahydrofuran — are mostly known in chemistry labs as inert solvents. A bimetallic base has now been shown to dismember this simple cyclic ether, breaking ...

ORGO earnings call for the period ending December 31, 2024.

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ETCompany ParticipantsGary S.

Image source: The Motley Fool. Organogenesis (NASDAQ: ORGO) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks ...

Organogenesis Holdings Inc (NASDAQ:ORGO) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $109.60 million, and the earnings are expected to ...

Gary S. Gillheeney, the President and CEO of $ORGO ($ORGO), sold 43,359 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing.

We recently compiled a list of the 10 Best NASDAQ Penny Stocks To Invest In. In this article, we are going to take a look at where Organogenesis Holdings Inc.